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This population-based study aimed to analyse variations in surgical treatment and guideline compliance with respect to the application
of radiotherapy and axillary lymph node dissection (ALND), for early breast cancer, before and after the sentinel node biopsy (SNB)
introduction. The study included 13532 consecutive surgically treated stage I–IIIA breast cancer patients diagnosed in 1989–2002.
Hospitals showed large variation in breast-conserving surgery (BCS) rates, ranging between 27 and 72% for T1 and 14 and 42% for
T2 tumours. In multivariate analysis marked inter-hospital and time-dependent variation in the BCS rate remained after correction for
case-mix. The guideline adherence was markedly lower for elderly patients. In 25.2% of the patients aged X75 years either ALND or
radiotherapy were omitted. The proportion of patients with no ALND after an SNB increased from 1.8% in 1999 to 37.8% in 2002.
However, in 2002 also 12.2% of the patients with a positive SNB did not have an ALND. Guideline compliance for BCS, with respect
to radiotherapy and ALND, fell since the SNB introduction, from 96.1% before 2000 to 91.4% in 2002 (Po0.001). Noncompliance
may however reflect patient-tailored medicine, as for elderly patients with small, radically resected primary tumours. The considerable
variation in BCS-rates is more consistent with variations in surgeon preferences than patient’s choice.
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The establishment of a nationwide mammography breast-screen-
ing program for women aged 50–74 years has resulted in an
increasing proportion of early breast cancers in the Netherlands
during the 1990s (Nab et al, 1993; van Dijck et al, 2000). Over the
last decade breast-conserving surgery (BCS) has become the
standard treatment for early stage breast cancer, as firm data have
shown that the outcome of BCS is comparable to the outcome after
modified radical mastectomy (MRM) in terms of disease-specific
survival (Veronesi et al, 1981; Fisher et al, 1985; EBCTG, 1995).
Most breast cancer treatment guidelines state that the expected
cosmetic outcome and patient preferences should guide the
decision to perform BCS. Several studies, however, have indicated
that surgical treatment for breast cancer may vary with the region
or the hospital in which a patient is treated (Farrow et al, 1992;
Nattinger et al, 1992; Voogd et al, 1994; Sainsbury et al, 1995;
Scorpiglione et al, 1995; Bland et al, 1998; Guadagnoli et al, 1998b;
Morrow et al, 2001). Although a large evidence base has been
accumulated defining the most effective treatment strategies for
early stage breast cancer, considerable treatment variability
remains both between and within countries (Malin et al, 2002).
Receiving less than appropriate care has been associated with an
increased risk of recurrence and lower breast cancer-specific
survival (Lash et al, 2000). Regular performance measurements,
using standardised clinical indicators, can play an important role
in monitoring the patterns of care with regard to cancer treatment
(Schneider et al, 2004).
This population-based study presents an overview of treatment
patterns for early stage breast cancer in the Netherlands over the
period 1989–2002. The aim of this study was to evaluate the
variation in primary surgical treatment and the compliance with
guidelines, with respect to the application of radiotherapy and
axillary lymph node dissection, with emphasis on the effect of the
sentinel node biopsy (SNB) introduction.
PATIENTS AND METHODS
Patients
All surgically treated stage I–IIIA (excluding TNM stages T3N0–
N2) breast cancer patients, diagnosed between January 1989 and
January 2003 in the North-Netherlands and treated with either BCS
or a MRM were eligible for inclusion. Patients with a prior invasive
cancer, patients who received neo-adjuvant chemotherapy prior to
surgery and patients with synchronous bilateral breast cancer, as
defined by a contralateral breast cancer diagnosed within
3 months, were excluded.
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A national breast-screening program, offering biennial mammo-
graphy to women aged 50–69 years, was gradually implemented in
the region since 1991. In 1997, all women in the target population
had been invited at least once and since 1999 women aged 70–74
were also invited. All women received mammography in two
directions for each breast: cranio-caudal and medio-latero-oblique.
Two radiologists evaluated the mammograms by a double,
independent reading. Women with a suspect mammogram were
referred to the surgical department of one of the hospitals in the
region for further evaluation.
Data collection by the cancer registry
Data were collected by the regional cancer registry of the
Comprehensive Cancer Center North (CCCN), covering the
Northern Netherlands, a mainly rural area with a population of
about 2.1million, served by 16 community hospitals, one
university medical centre, four radiotherapy facilities and seven
pathology laboratories. PALGA, the nationwide Dutch network
and registry of histo- and cytopathology, regularly submits reports
of newly diagnosed malignancies to the cancer registry. The
national hospital discharge databank, which receives discharge
diagnoses of admitted patients from all Dutch hospitals, completes
case ascertainment. After notification, trained registry personnel
collect data on diagnosis, staging, and treatment from the medical
records, including pathology and surgery reports. All primary
treatment received is coded in sequence of administration. Patients
are staged according to the TNM system of the UICC (Hermanek
and Sobin, 1992; Sobin and Wittekind, 1997).
Guidelines
The prevailing treatment guidelines for the study period are briefly
outlined below. For patients with a tumour o4cm, BCS with
axillary lymph node dissection (ALND) was indicated, comple-
mented with radiotherapy to the whole breast and a boost to the
tumour excision area. The guidelines indicated that the surgical
treatment should be based on the expected cosmetic outcome
(tumour to breast ratio) and the patients’ preferences. Alterna-
tively, an MRM was performed. Loco-regional radiotherapy,
consisting of parasternal, axillary, infra and supraclavicular nodal
irradiation, was indicated in case of 43 positive axillary nodes or
extranodal axillary growth. Parasternal irradiation was indicated
for node-positive patients with a medially located tumour.
Until 2000 ALND was indicated for all patients, after which a
sufficient number of lymph nodes, at least 6 until 1998 and 10
thereafter, had to be pathologically examined. Since 2000 the
guideline included the option of performing an SNB, for which
a combined detection method was advised comprising peri-/
intratumoral radioactive tracer injection and lymphoscintigraphy
one day before surgery and blue dye injection at induction of
anaesthesia. When a positive SNB was detected an ALND was
indicated. Surgeons with sufficient, documented, experience with
the SNB procedure (430 SNB procedures with ALND as part of a
learning curve) were allowed to omit ALND in patients with a
negative SNB.
For the evaluation of guideline compliance, breast-conserving
therapy was scored as ‘appropriate’ when it included an ALND and
was complemented with radiotherapy; an MRM was considered in
accordance with the guideline if complemented by an ALND.
Omission of ALND was allowed after a negative SNB. An ALND
with 43 positive nodes was considered an indication for regional
radiotherapy, omission of radiotherapy was scored as ‘inappropri-
ate’. Omission of radiotherapy for node-positive medially located
tumours was also scored as ‘inappropriate’ in the evaluation of
guideline adherence.
Statistical analysis
The pathological tumour size was used to assess the choice of
surgical treatment. In univariate analysis the w
2 test was used to
examine the associations of categorical variables with the
proportion of patients treated with BCS. The inter-hospital
variation in the proportion of BCS was studied with Poisson
regression analysis, adjusting for various patient and tumour
characteristics. The rate of BCS was estimated against the regional
average BCS rate as reference. Variables considered in the model
were the hospital, patient age (o40, 40–49, 50–59, 60–69, 70–79
and 80þ), tumour localisation in the breast (central/nipple,
medial, lateral, overlapping), tumour size (p1cm or T1a/1b,
1–2cm or T1c, 2.1–5cm or T2), year of diagnosis (1989–1991,
1992–1994, 1995–1997, 1998–2000, 2001–2002), mode of detec-
tion (screen-detected vs non-screen-detected) and distance from
the nearest radiotherapy facility. Furthermore, first-order interac-
tions of significant variables were tested (hospital with period of
diagnosis, age at diagnosis and tumour size). Model fit was
evaluated using the Pearson w
2 goodness-of-fit test statistic
(McCullagh and Nelder, 1989). All reported P-values are two
sided. A P-value o0.05 was considered significant.
RESULTS
Type of surgery
Between January 1989 and January 2003, 13532 consecutive
patients were included. Table 1 shows some patient characteristics
for patients receiving BCS. In total, 41.2% of the patients received
BCS, 52.1% for a T1 and 26.5% for a T2 tumour. The proportion of
patients treated with BCS varied markedly between the hospitals,
ranging from 27.2 to 71.9% for T1 and from 13.5 to 42.3% for
T2 tumours. Following a decrease between 1989 and 1995, the
proportion receiving BCS gradually increased since 1996 for both
T1 and T2 tumours (Figures 1 and 2). The initial decrease was
most pronounced for patients o50 years, whereas for patients of
70þ years the BCS rate remained more or less stable until 1996.
Screen-detected tumours were better candidates for BCS. The
screen-detected T1 tumours were smaller than non-screen-
detected tumours. The proportion of tumours p1 (T1A/B) and
1–2cm (T1C) were 36.5 and 63.5% for screen-detected vs 20.6 and
79.4% for non-screen-detected tumours, respectively (Po0.001).
Furthermore, since the completion of the implementation phase of
the screening program for women aged 50–69 years, the
proportion of nonpalpable screen-detected tumours increased
from 44.2 in 1997 to 57.3% in 2002. Therefore, patients with
screen-detected tumours actually were more likely to receive BCS
(Table 2). Patients aged 50–69 and 70–74 years with a screen-
detected T1 tumour had a, respectively, 1.15 (95% CI 1.08–1.22)
and 1.81 (95% CI 1.55–2.10) fold higher relative risk (RR) of
receiving BCS. For the T2 tumours these figures were 1.37 (95% CI
1.20–1.56) and 2.14 (95% CI 1.48–3.09), respectively. The rate of
BCS decreased with older age, with the notable exception of
screen-detected T1 tumours. Only 23.1% of the patients X70 years
underwent BCS, compared to 49.8% of patients o50 years. Over
the age of 80 years, BCS was applied in 17% of the patients with a
T1 and 8.7% with a T2 tumour.
The distance from the municipality, where the patient lived, to
the nearest radiotherapy facility correlated negatively with the
proportion of patients receiving BCS, although the distance rarely
exceeded 80km. The trend of a decreasing rate of BCS with
increasing distance from a radiotherapy facility was seen for all age
groups, with the exception of patients X70 years with T2 tumours,
and persisted over time. However, stratified by hospital, the
association between distance from a radiotherapy facility and BCS
disappeared, indicating that hospital could also explain the
observed association.
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In a Poisson regression analysis, older age, larger tumour size,
lobular histology, central location or overlapping quadrants and a
non-screen-detected cancer were all independently associated with
a decreased BCS rate. Compared to patients with T1 tumours a
patient with a T2 tumour had a RR of 0.58 (95% CI 0.54–0.63) of
receiving BCS. Compared to patients o50 years, the RR of
receiving BCS were 0.98 (95% CI 0.88–1.10), 0.87 (95% CI 0.77–
0.97), 0.74 (95% CI 0.65–0.83), 0.52 (95% CI 0.46–0.60) and 0.26
(95% CI 0.21–0.32) for the 50–59, 60–69, 70–74, 74–79 and 80þ
year age groups, respectively. A lobular histology decreased the
rate of BCS by 26% (RR 0.74, 95% CI 0.66–0.82) and central
tumour location or a tumour in overlapping quadrants decreased
the rate of BCS with 18% (RR 0.82, 95% CI 0.75–0.89) and 31%
(RR 0.69, 95% CI 0.60–0.80), respectively, compared to lateral or
medial tumours. A non-screen-detected tumour was associated
with a decreased BCS rate (RR 0.83, 95% CI 0.77–0.89). Even after
correction for case mix, marked inter-hospital variation in the BCS
rate remained. Following tumour size and patient age, the
individual hospital was the most important variable predicting
the likelihood of BCS (Figure 3). A strong effect of modification
was found by year of diagnosis, the effect of time varying
significantly between the hospitals (Table 3).
Adjuvant radiotherapy after BCS
Of the 5577 patients who received BCS as definitive surgical
therapy, 96.5% received radiotherapy. Withholding radiotherapy
after BCS was associated with age. Whereas 97.7% of the patients
o70 years received radiotherapy, these figures were 95.8, 90.9
and 57.4% for patients aged 70–74 years, 75–79 and X80 years,
respectively (Po0.001). Furthermore, the proportion of patients
not receiving radiotherapy after BCS differed between the areas
covered by the three regional radiotherapy facilities (5.0, 3.5 and
1.7%, respectively, Po0.001). Differences in treatment policy for
the older patients partly explained this finding, as 63.2, 67.6 and
92.6% of the patients aged X75 years received radiotherapy after
BCS in the three radiotherapy facilities, respectively (Po0.001).
Over time, the proportion of patients receiving radiotherapy
following BCS remained stable, but the number of patients treated
increased 2.7-fold between 1989 and 2002.
Radiotherapy after MRM
Of the 7955 patients treated with an MRM, 21.6% subsequently
received radiotherapy. Of these patients, 70.9% either had
extensive lymph node involvement or a node-positive medial
tumour. Of the patients who did not receive radiotherapy, 10.4%
had these radiotherapy indications. Older patients were less likely
to receive radiotherapy when indicated. Of the patients with a
radiotherapy indication aged X75 years, 52.9% actually received
radiotherapy compared to 69.2% of the patients o75 years
(Po0.001). Although the proportion of patients treated with
radiotherapy differed slightly between the three radiotherapy
facilities, after adjusting for radiotherapy indication this difference
disappeared (P¼0.254). Both the proportion and number of
patients receiving radiotherapy after MRM remained stable over
time.
Axillary lymph node dissection and SNB
Before 2000, only 1.8% of the patients did not have an ALND (2.1%
with a T1 and 1.4% with a T2 tumour). The proportion of patients
without ALND increased from 1.0% in 1989 to 2.4% in 1998 and
increased markedly with older age in this period, totalling 7.9%
among patients aged X80 years. The SNB was introduced at the
end of 1998 and during 1998–2000 most patients received ALND
after an SNB, as part of the surgeon’s learning curve. Since 2000
the proportion of patients receiving an SNB increased. In 2002 only
34.8% of the patients still underwent an ALND without a prior SNB
(Figure 4). The proportion of patients who underwent an SNB
without a subsequent ALND increased steadily from 1.8% in 1999
to 37.8% in 2002. The proportion of patients without ALND after a
positive SNB increased markedly in 2002 to 12.2%.
Adherence to the guidelines for primary treatment
Table 4 illustrates the guideline adherence for early stage breast
cancer. Following BCSn 95.0% of the patients underwent an ALND
and subsequently received radiotherapy. The guideline adherence
for breast-conserving therapy decreased following the SNB
introduction, from 95.6% in 1999 to 91.3% in 2002 compared to,
on average, 96.8% in the previous years (Po0.001). During 2001–
2002, 3.1% of the patients treated with BCS did not have
radiotherapy, 4.2% did not have ALND and in 1.3% both
radiotherapy and ALND were omitted. Of the patients with no
Table 1 Characteristics of all patients and those receiving breast-
conserving surgery (BCS)
All patients
Patients receiving BCS
Number Number %
Tumour location
Central 878 239 27.2
Medial 2788 1260 45.2
Lateral 6708 2950 44.0
Overlapping 3158 1128 35.7
Tumour size
T1A/B 2023 1178 58.2
T1C 5766 2878 49.9
T2 5743 1521 26.5
Age (years)
o50 3473 1718 49.5
50–69 6645 3079 46.3
70–74 1450 478 33.0
75+ 1964 302 15.4
Total number of patients treated per hospital
Average 712 293 41.2
Range 222–2231 63–793 21.5–60.8
Distance from radiotherapy department (km)
0–9.9 2439 1111 45.6
10–24.9 2681 1149 42.9
25–44.9 5470 2266 41.4
45+ 2896 1025 35.4
Year of diagnosis
1989–1991 2145 769 35.9
1992–1994 2667 897 33.6
1995–1997 2951 1049 35.5
1998–2000 3265 1531 46.9
2001–2002 2504 1331 53.2
Mode of detection
Screen detected 3327 1830 55.0
Non-screen detected 10205 3747 36.7
Histology
Ductal carcinoma 11484 4943 43.0
Lobular carcinoma
a 1429 430 30.1
Other
b 617 203 32.9
aIncluding mixed lobular and ductal carcinoma.
bMucinous, medullary, unspecified.
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conserving therapy guidelines decreased with older patient age
(Po0.001). During 1989–2002, 25.2% of the patients aged X75
years received ‘inappropriate’ breast-conserving therapy (omission
of radiotherapy, ALND or both). Guideline compliance for breast-
conserving therapy was lower following the SNB introduction in all
age groups.
Guideline compliance for patients treated with an MRM
averaged 90.6%, predominantly due to omission of radiotherapy
for patients with (extensive) lymph node involvement. Of the 1642
patients with 43 positive (or fixed nodes/extracapsular tumour
extension) axillary nodes, 39.4% did not receive radiotherapy
although it was indicated. When indicated, radiotherapy was more
frequently omitted in patients o50 years or X75 years compared
to patients aged 50–74 years. In 1.8% of the patients an ALND was
incorrectly omitted; this proportion increased with older age and
in the most recent years. The guideline compliance was lowest for
patients aged X75 years due to relatively frequent omission of
either radiotherapy or ALND.
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Figure 1 Inter-hospital variation in the proportion of T1 tumours treated with breast-conserving surgery (BCS) by year of diagnosis. The square
represents the regional average; the bars represent the range between all hospitals.
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Figure 2 Inter-hospital variations in the proportion of T2 tumours treated with breast-conserving surgery (BCS) by year of diagnosis. The square
represents the regional average; the bars represent the range between all hospitals.
Table 2 Breast-conserving surgery (BCS) rate according to the mode of
detection, age and tumour size
T1 T2
BCS Total BCS Total
Mode of detection Age (years) % N % N
Non-screen detected o50 60.4 1876 36.0 1535
50–69 52.0 1969 27.5 1874
70–74 33.8 488 14.9 545
75+ 19.5 826 10.5 1092
Total 48.1 5159 25.0 5046
Screen detected o50 58.0 50 25.0 12
50–69 59.5 2210 38.0 592
70–74 61.2 335 32.9 82
75+ 68.6 35 18.2 11
Total 59.8 2630 36.9 697
Type of surgery and guideline adherence in breast cancer
M Schaapveld et al
523
British Journal of Cancer (2005) 93(5), 520–528 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sDISCUSSION
In this population-based study, large inter-hospital variation in
BCS was observed, which persisted after adjustment for case-mix.
Following tumour size and age, the individual hospital was the
most important variable predicting the likelihood of receiving BCS.
Generally, hospitals, which scored far under or above the regional
average, did so during the whole study period. The time trend for
BCS varied significantly between the hospitals. Besides changes in
doctors and patients attitudes towards BCS, changes in the surgical
staff are a possible explanation for this observation. It is very likely
that the observed inter-hospital variation in BCS reflects surgeon
preference more than patient preference.
A study evaluating the effect of an interactive treatment decision
aid in a Dutch patient population (N¼172) showed that the
patients’ perception of her physicians’ treatment preference was an
important factor in decision making (Molenaar et al, 2004). In a
population-based study, Katz et al found that patients who did not
feel they had had a choice between surgical options perceived less
satisfaction with the decision-making process (Katz et al, 2001).
Informed decision making by the patient does not necessarily
imply that a patient will choose BCS, however. A survey among
1489 patients in the Detroit and Los Angeles metropolitan area,
performed shortly after surgery, found that patients who felt
involved in the decision making were actually more inclined to
accept MRM, whereas patients who underwent BCS felt more
frequently that their surgeon made the treatment decision (Katz
et al, 2004). In a study in Western Australia, women who received
BCS also reported a more important role of the surgeon’s
preference in their decision-making than those who had had an
MRM (Mastaglia and Kristjanson, 2001). A study, evaluating a
decision board to help surgeons inform breast cancer patients
about their treatment options, also had interesting effects. While
the surgeons stated that the instrument improved communication
and facilitated shared decision-making, the rate of BCS decreased
after its introduction (Whelan et al, 1999). It remains therefore
Table 3 Results of multivariate Poisson regression analysis for variation in the rate of breast-conserving surgery (BCS) and estimated rate ratios (RR) of
BCS by hospital for each period of diagnosis (with 1989–1991 as reference)
Time trend for BCS
1989–1991 1992–1994 1995–1997 1998–2000 2001–2002
RR
a 95% CI RR RR RR RR RR
Hospital
Hospital A 1.89 1.14–3.12 1.00 0.72 0.83 0.99 1.14
Hospital B 1.87 1.18–2.95 1.00 0.85 0.84 0.97 0.98
Hospital C 1.93 1.06–3.50 1.00 0.40 0.88 0.92 1.01
Hospital D 1.38 0.80–2.37 1.00 1.09 0.98 1.11 1.51
Hospital E 1.68 1.02–2.76 1.00 0.83 0.81 0.78 0.95
Hospital F 1.30 0.79–2.12 1.00 0.97 1.03 1.22 1.43
Hospital G 1.66 0.95–2.89 1.00 0.78 1.02 0.62 0.74
Hospital H 0.96 0.63–1.46 1.00 1.15 0.95 1.64 1.58
Hospital I 0.91 0.51–1.61 1.00 0.92 0.95 1.69 1.88
Hospital J 1.04 0.61–1.75 1.00 0.81 0.73 1.39 1.66
Hospital K 1.26 0.68–2.31 1.00 0.77 0.77 0.85 0.87
Hospital L 0.61 0.34–1.10 1.00 1.63 1.55 1.86 2.30
Hospital M 0.71 0.37–1.36 1.00 1.05 0.81 1.45 2.54
Hospital N 0.98 0.61–1.56 1.00 0.79 0.67 1.36 1.38
Hospital O 0.53 0.25–1.14 1.00 1.10 1.81 2.33 2.94
Hospital P 1.03 0.57–1.86 1.00 1.00 0.94 1.31 0.58
Hospital Q 1.63 0.80–3.32 1.00 0.52 0.52 0.56 0.71
Hospital R 0.61 0.31–1.17 1.00 1.23 0.88 2.19 1.46
Hospital S 0.58 0.26–1.27 1.00 1.00 1.02 1.38 1.06
aRelative risk of BCS for the period 1989–1991 vs the regional average BCS rate, adjusted for age, tumour size, period of diagnosis, histology, location and mode of detection.
95% CI: 95% confidence interval for RR.
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Figure 3 Estimated rate ratios with 95% confidence intervals for breast-
conserving surgery (BCS) by hospital (denoted by the letters A–S) vs the
regional average BCS rate (reference is 1.0) in the Comprehensive Cancer
Center North region 1989–2002 (hospital with o500 patients , with
500–999 patients and with X1000 patients diagnosed between
1989 and 2002).
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as a standard for good quality of care. Nevertheless, several studies
have shown that various quality of life indicators may differ
between patients treated with BCS or MRM (Ganz et al, 1992; Pozo
et al, 1992; Poulsen et al, 1997; Arora et al, 2001; Janni et al, 2001;
Engel et al, 2004). Recently, it was shown that patients who
underwent an MRM scored worse on body image, sexual
functioning and lifestyle disruption compared to patient treated
Table 4 Guideline adherence for axillary lymph node dissection (ALND) and radiotherapy (RT) in breast cancer treatment, by type of surgery, age and
period of diagnosis
Therapy not according to guideline Therapy according to guideline
No ALND No RT No RT and no ALND
Total
Type of surgery N % N % N % N % N
BCS
Total 88 1.6 133 2.4 60 1.1 5296 95.0 5577
Age (years)
o50 14 0.8 38 2.2 1 0.1 1665 96.9 1718
50–69 60 1.9 55 1.8 12 0.4 2952 95.9 3079
70–74 4 0.8 14 2.9 7 1.5 453 94.8 478
75+ 10 3.3 26 8.6 40 13.2 226 74.8 302
Year of diagnosis
1989–1991 1 0.1 23 3.0 — — 745 96.9 769
1992–1994 1 0.1 30 3.3 3 0.3 863 96.2 897
1995–1997 8 0.8 6 0.6 8 0.8 1027 97.9 1049
1998–2000 22 1.4 32 2.1 32 2.1 1445 94.4 1531
2001–2002 56 4.2 42 3.2 17 1.3 1216 91.4 1331
MRM
Total 116 1.5 628 7.9 2 0.0 7209 90.6 7955
Age (years)
o50 12 0.7 185 10.5 — — 1558 88.8 1755
50–69 17 0.5 229 6.4 1 0.0 3319 93.1 3566
70–74 9 0.9 60 6.2 — — 903 92.9 972
75+ 78 4.7 154 9.3 1 0.1 1429 86.0 1662
Year of diagnosis
1989–1991 23 1.7 74 5.4 — — 1279 93.0 1376
1992–1994 19 1.1 158 8.9 — — 1593 90.0 1770
1995–1997 18 0.9 178 9.4 — — 1706 89.7 1902
1998–2000 28 1.6 120 6.9 — — 1586 91.5 1734
2001–2002 28 2.4 98 8.4 2 0.2 1045 89.1 1173
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Figure 4 Time trend for sentinel lymph node biopsy and axillary lymph node dissection for breast cancer in the Comprehensive Cancer Center North
region 1995–2002.
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swith BCS, while these scores did not improve over time in either
patient group (Engel et al, 2004). Previous studies also reported
that especially younger patients scored particularly worse on body
image after an MRM than patients treated with BCS (Ganz et al,
1992; Arora et al, 2001).
The proportion of patients treated with BCS in our population
was comparable to that in the USA, according to the data from the
SEER registry (Lazovich et al, 1999). In the Southeast-Netherlands,
67% of stage I and 43% of stage II breast cancers received BCS in
1990–1991 (Voogd et al, 1994), proportions which were attained
only in some hospitals in our region.
A temporary decrease in the BCS rate was observed during
the mid-1990s. We can only speculate about the cause. The
decrease manifested following publications showing an increased
local recurrence risk after BCS for patients with larger tumours,
tumours with an extensive in situ component and for patients
younger than 40 years (Delouche et al, 1987; Bartelink et al,
1988; Boyages et al, 1990; Lichter et al, 1992). Also, in this
period the breast-screening program rapidly expanded, which
may have resulted in logistic problems in hospitals and radio-
therapy facilities. The number of patients diagnosed with early
stage breast cancer increased almost 40% in the period 1995–1997
compared to 1989–1991. On the other hand, in our study actually
patients with screen-detected, early stage breast cancer were
more likely to receive BCS, even after adjusting for tumour size.
A study in the Southeast-Netherlands also found a higher
likelihood of BCS for patients with screen-detected cancers,
although this study did not correct for differences in tumour size
between screen-detected and non-screen-detected cancers (Ernst
et al, 2001).
Primary therapy generally was given in accordance with the
guidelines. In all, 95% of the patients treated with BCS underwent
ALND and received radiotherapy. Most patients (98.5%) had an
ALND as part of an MRM. These results compare favourably with
studies from the USA (Guadagnoli et al, 1998b; Lazovich et al,
1999; Nattinger et al, 2000; Morrow et al, 2001). Nattinger et al
observed an increasing trend of inappropriate treatment of early
stage breast cancer in the SEER database, mainly due to an
increased proportion of patients receiving breast-conserving
therapy and the higher likelihood of inappropriate breast-
conserving therapy (omission of ALND, radiotherapy or both)
compared to MRM; 19% of the patients treated in 1995 received
incomplete treatment (Nattinger et al, 2000). In our population,
the proportion of patients treated in accordance with the guideline
fell since 1998, following the introduction of the SNB, frequently
due to omission of ALND. Several studies have reported lower use
of ALND and postoperative radiotherapy in the elderly patient
(Voogd et al, 1994; Guadagnoli et al, 1998a; Hebert-Croteau et al,
1999; Edge et al, 2002; Giordano et al, 2005). The benefit of ALND
for elderly patients has been seriously questioned in the literature
(Wazer et al, 1994; Newlin et al, 2002; Martelli et al, 2003) and
surgeons may be reluctant to perform an additional ALND
(following BCS or SNB) in elderly patients as they frequently
suffer from comorbidity. Over the years 2001–2002, in our study
50% of the patients who did not have an ALND had a tumour
positive SNB; most of these patients were over 50 years of age. One
could argue that the outcome of ALND in this group of patients
would not often change the projected adjuvant treatment and as
such may represent appropriate patient-tailored medical practice.
In our population radiotherapy, as part of BCS, was omitted in
22% of the patients aged X75 years. A recent CALGB-study,
comparing lumpectomy plus tamoxifen with and without radiation
in women with clinical stage I breast cancer aged X70 years, found
only a small nonsignificant excess risk of local recurrence in the
nonirradiated group and no differences in distant metastases risk
or survival (Hughes et al, 2004). Another recent study examined
local recurrences rates among patients who refused radiotherapy
or had medical contraindications and found low local recurrence
rates among elderly patients with small, lower grade tumours
operated with adequate resection margins (Lee et al, 2004).
Although inappropriate according to the guideline, omitting
radiotherapy after BCS in the very elderly appears to be reasonable
medical practice for elderly patients with small, adequately
resected tumours.
The prevailing guideline for elective nodal irradiation was
largely based on the extent of nodal involvement during the study
period. A relatively recent meta-analysis showed that postoperative
locoregional radiotherapy resulted in a survival advantage for
high-risk patients (Whelan et al, 2000). Other studies have shown
that even after an adequate axillary dissection and adjuvant
systemic therapy, a high risk of locoregional recurrence remained in
patients with a high number of involved nodes when these patients
did not receive postoperative radiotherapy (Ragaz et al, 1997;
Recht et al, 1999). Although it is as yet not completely clear which
patients do need locoregional radiotherapy, in the Netherlands
the current guidelines advise to give axillary and supraclavicular
radiotherapy in case of 43 positive axillary lymph nodes or a
positive apical node. In our study, 39% of the patients treated with
an MRM for whom radiotherapy was indicated according to this
guideline actually were not irradiated. Comorbidity and older age
have previously been associated with decreased use of loco-
regional radiotherapy (Ballard-Barbash et al, 1996; Hebert-Croteau
et al, 1999; Morrow et al, 2001). There is a need for guidelines,
which better address treatment issues in the elderly breast cancer
patient, especially as the elderly comprise a growing proportion of
our patient populations.
This study provides an evaluation of current treatment
patterns for breast cancer. To ensure that these results would
improve the quality of care, the data were presented to delegations
from all regional hospitals, including delegates from the
surgical staff, during three invitational conferences in the first
half of 2005. Unit names were not removed in these presentations.
The variation in BCS has been discussed repeatedly within the
Comprehensive Cancer Center North (CCCN) breast cancer
working group and more recently within the Surgical Oncological
Network North Netherlands, a CCCN working group comprising
surgeons from all hospitals in the CCCN region. As a result of
these discussions, the CCCN cancer registry provides since 2003,
among other data, stage and age specific rates of BCS for each
hospital in the CCCN region. These data are regularly discussed
within the Surgical Oncological Network North Netherlands,
during which the results of individual units are opened to all
other hospitals and are compared to the regional average and
that of other centres. Largely as a result of these discussions we
have seen a marked increase in the proportion of patients treated
with BCS.
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